HIV Prevention 2019

HIV_Prevention2019_Theme_Banner_v5

About the Program:

Program Overview
Target Audience
Learning Objectives
Faculty
Joint Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Method of Participation and Request for Credit
Disclosure of Unlabeled Use
Disclaimer
Computer System Requirements

Program Overview:

While there has been significant progress in the prevention of new HIV infections, transmission of HIV continues. Clearly, more needs to be done to reduce the rate of new infections through such approaches as increased HIV testing, behavioral interventions and the use of pre-exposure prophylaxis (PrEP). However, many clinicians are not fully equipped to guide their patients through the complex issues associated with HIV prevention. This situation results in patients not receiving optimal preventative care as described in national guidelines and to an increased number of people becoming infected with HIV who might otherwise not be infected.

This educational program has been designed to address these challenges. This program will include case studies to educate clinicians who work with various patient populations - especially high-risk patients - about the theoretical framework, latest findings and ongoing research in this field, and to review the professional guidelines in this area. In addition, this program will educate clinicians with strategies to provide improved prevention services to patients, which is expected to help reduce the number of new HIV infections.

Back to Top

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Learning Objectives:

Upon completion of the program, participants should be able to:

Describe and recognize in clinical practice risk factors that contribute to the continued spread of HIV, especially in high-risk populations
Obtain a full and accurate history from patient regarding their risk factors for contracting or transmitting HIV
Identify barriers to prevention and conduct effective discussions with patients about methods to reduce the spread of HIV infection
Characterize and apply in clinical practice strategies to reduce the risk of new infections with HIV in various populations, including barrier methods, treatment as prevention, PrEP and PEP

Release Date: May 14, 2019

Expiration Date: May 14, 2020

Estimated time to complete each Module: 30 - 60 minutes

Media: Internet

Computer System Requirements: Internet Connection and Browser

Back to Top

Faculty:

W. David Hardy, MD
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Washington, DC

Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania

Michael Sension, MD
Medicial Director
CAN Community Health
Ft. Lauderdale, Florida

Pablo Tebas, MD
Professor of Medicine
Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Back to Top

Joint Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Back to Top

Credit Designation:

Case Module 1 (HIV Risk Factors in High-Risk Populations):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 2 (HIV Assessment and Prevention Strategies):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 3 (Identifying Barriers to HIV Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Module 4 (Clinical Strategies to Reduce HIV Risk in Various Populations):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

David Hardy, MD:

Consulting Fees: Gilead, Merck, ViiV/GSK
Contracted Research: Amgen, Gilead, Janssen, Merck, ViiV/GSK

Helena Kwakwa, MD:

No real or apparent conflicts to disclose

Michael Sension, MD:

Consulting Fees: Janssen, Gilead, ViiV
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents: Janssen, Gilead, ViiV

Pablo Tebas, MD:

Consulting Fees: Gilead, ViiV, Merck

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Back to Top

Method of Participation and Request for Credit:

There are no fees for participating and receiving CME/CE credit for this activity. During the period, May 14, 2019 through May 14, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14176. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements:

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.